Fujirebio
Fujirebio, Sysmex to Collaborate on Immunoassay Development
The firms will explore a wide range of potential collaborations, including research and development, production, clinical development, and sales and marketing.
Top Five Articles on 360Dx Last Week: Prison for Lab Owner; Grail's Cancer Detection Deal; More
Last week, readers were most interested in a 27-year prison term handed down for a $463 million scheme to defraud Medicare.
Beckman Coulter, Fujirebio Collaboration Targeting Alzheimer's, Other Neurodegenerative Diseases
Premium
The firms announced last month that they will develop tests for neurodegenerative diseases to run on Beckman Coulter's instruments.
Alzheimer's Dx Firms Aim to Take Advantage of Increased Testing Demand Following Leqembi Approval
Premium
Near term, CSF assays and PET imaging will likely remain the methods of choice for evaluating patients for the drug, but blood tests continue to gain traction.
Beckman Coulter, Fujirebio Partner to Develop Blood-Based Alzheimer's Tests
The partnership will expand the menu on Beckman Coulter's Access portfolio of immunoassay analyzers.